Semaglutide injection (Wegovy; Novo Nordisk) now has an additional indication for the reduction of major adverse cardiovascular events in adults with established CVD and either overweight or obesity, ...
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC.
The analyses included 3389 adults with a body mass index of at least 30.0kg/m2 who initiated semaglutide or liraglutide for obesity or type 2 diabetes. (HealthDay News) — For patients with obesity ...
Weight reduction at one year linked to medication active agent, dosage, treatment indication, persistence of coverage. HealthDay News — For patients with obesity receiving semaglutide or liraglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results